Sunday, December 08, 2013 11:12:09 AM
There are pros and cons to the stock that should be able to be discussed without animus.
For me, the pros are basically the technology. Apple has verified, with their investment, that LQMT may have something valuable.
The cons is the time that it is taking to really bring this to market and what it has done to the share structure of the company. It will be hard to really see the share price appreciation that some here are talking about with the present number of outstanding shares. Also, the longer it takes to bring this to market, the greater the chance the next great thing might come up and make LQMT irrelevant.
The unknown is if and when the company will be able to bring something that will be a big commercial success to market before the share structure waters down the value each share has more significantly. From my standpoint, I don't see that management has been bad about all of this. Especially with small, undercapitalized companies, it can take much longer(if ever) than expected for things to come to fruition. It is the reason why the share price is where it is at right now. There is great promise but will it ever be fulfilled is the big question that will need to be answered.
My position right now is to hold my present shares that my cost basis is around 30 cents a share. If there is a runup in the stock from here, I might take some money off of the table and leave a certain amount for some speculation. But everybody's risk/reward ratio is different and I understand why some may want to bail right now and why some are still buying.
Recent LQMT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 10:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 10:26:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 08:41:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM